14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
QNRX vs HSDT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Solana Company (HSDT) is the stronger overall head-to-head candidate over Quoin Pharmaceuticals, Ltd. (QNRX) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). QNRX carries a Unified Composite Score of 47.1/100 (HOLD) at $3.36 (N/M Forward P/E, 0.0% operating margin), whereas HSDT carries 59.0/100 (HOLD) at $1.66 (N/M Forward P/E, -1557.5% operating margin).
Technical & Structure Timing Caution: QNRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.8); meanwhile HSDT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on QNRX vs HSDT. Trailing 12-month operating profitability (QNRX 0.0% vs HSDT -1557.5%) and valuation multiples (QNRX N/M vs HSDT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $17.1M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
HSDT Moat ProfileHigh-Margin Pricing Power Moat
Asset Management Operator
Competes within the Asset Management value chain with $103.1M market capitalization and -1557.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ QNRX vs HSDT Key Questions & Quantitative Answers
As of Nov 19, 2026, Solana Company (HSDT) is the stronger overall head-to-head candidate over Quoin Pharmaceuticals, Ltd. (QNRX) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). QNRX carries a Unified Composite Score of 47.1/100 (HOLD) at $3.36 (N/M Forward P/E, 0.0% operating margin), whereas HSDT carries 59.0/100 (HOLD) at $1.66 (N/M Forward P/E, -1557.5% operating margin). Technical & Structure Timing Caution: QNRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.8); meanwhile HSDT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
HSDT leads the Growth & Scale pillar: QNRX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with HSDT at +382.1% YoY revenue growth and +0.0% YoY earnings growth on $272M TTM revenue (92.8% gross margin, -1557.5% operating margin). On trailing 12-month operating scale, QNRX generates N/A in USD-normalized revenue versus $272M for HSDT. In operating R&D and SG&A reinvestment, QNRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for HSDT.
HSDT screens cheaper on headline valuation multiples. QNRX trades at N/M Forward P/E, 8.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas HSDT trades at N/M Forward P/E, 0.0x Trailing P/E, N/M PEG, and 0.4x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against QNRX (-142.6% ROE) versus HSDT (52.8% ROE) capital efficiency.
In options market volatility and institutional positioning, QNRX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.35β · 72% Vol realized risk). By comparison, HSDT carries 540.7% implied volatility (85th %ile, Extreme (>80th %ile)), a 7.50x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.20β · 55% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.